For years, cell therapy news has circled one question: does it work at all? In several blood cancers that question is largely settled. The more useful question now is which approach works better, and for whom. Three recent trial updates show the field moving in that direction.
A direct comparison in lymphoma
Lyell Immunopharma has launched what is described as the first head-to-head CAR-T trial in lymphoma. Rather than measuring a therapy against a historical benchmark, a head-to-head design runs two treatments through the same protocol and compares efficacy, safety and durability directly.
That matters because cross-trial comparisons are shaky. Patient populations, prior treatments and endpoints differ from one study to the next, which leaves doctors and payers guessing about relative value. A direct comparison removes much of the guesswork. The details of the first head-to-head CAR-T lymphoma trial are worth a read for anyone following treatment sequencing.
Matching AML patients to the right drug
SELLAS Life Sciences has enrolled the first patient in a randomized Phase 2 study of SLS009, a CDK9 inhibitor, in newly diagnosed acute myeloid leukemia (AML). The trial focuses on patients who are less likely to respond to standard venetoclax-based regimens, and it uses biomarkers to select participants.
Enrichment of this kind raises the odds of seeing a real signal in the people most likely to benefit, and it avoids burying results under patients who would have done fine on standard care. SELLAS’s biomarker-driven AML study is a clear example of precision selection reaching leukemia.
A quiet but important finish line
Senti Biosciences has completed enrollment in its SENTI-202 Phase 1 trial in AML. Phase 1 studies mainly look at safety, dosing and early biological activity, so closing enrollment is less a victory lap than a handoff. The program now moves toward its first data readouts. In a disease with high unmet need, even early data will draw attention.
What to watch next
Three questions will decide how much these updates matter. Will the head-to-head results show a clear difference in durability and safety? Does biomarker selection translate into better responses in AML? And do early cell therapy readouts hold up in larger groups of patients? None has an answer yet, but the way these studies are built suggests the answers will be easier to trust than earlier ones.
For readers tracking this space, the practical takeaway is simple: judge trials on design quality as much as on response rates. A well-built comparison or a well-chosen biomarker can be more informative than a bigger headline number.
Conclusion
Cell therapy is leaving its proof-of-concept era. Direct comparisons, smarter patient selection and steady early-phase progress give clinicians something more useful than excitement: evidence they can actually compare.


